The World Health Organization (WHO) granted its first Emergency Use Listing (EUL) for a molecular diagnostic test for the Bundibugyo virus (BDBV) on July 2, 2026. This move aims to accelerate case confirmation during an ongoing outbreak that has resulted in 1,460 confirmed cases and 452 deaths in the Democratic Republic of Congo (DRC), with additional cases reported in Uganda.
How does the new diagnostic test function?
The newly cleared test identifies the Bundibugyo virus by detecting its specific genetic material within human blood samples. According to the WHO, this molecular approach allows for rapid and accurate confirmation of infection, which is a critical step in isolating patients and interrupting transmission chains.
Diagnosing this specific strain remains difficult because its symptoms mirror other endemic febrile illnesses, most notably malaria. Without laboratory confirmation through PCR or antigen-based assays, healthcare workers struggle to distinguish BVD from common regional fevers. The EUL designation ensures that these diagnostic tools meet international quality and safety standards, specifically tailored for the resource-constrained environments of low- and middle-income nations.
The Bundibugyo virus is one of the rarest strains of the Ebola family. Before the current 2026 epidemic, it had been identified in only two previous documented outbreaks.
What is the current status of the outbreak in Africa?
As of July 2, 2026, the WHO and the Africa Centres for Disease Control and Prevention (Africa CDC) have expanded testing capacity to a network of 10 laboratories across affected regions. These facilities now possess the capacity to perform over 2,000 tests per day.
While 229 patients have successfully recovered—213 in the DRC and 16 in Uganda—the situation remains fluid. The WHO officially declared the outbreak a Public Health Emergency of International Concern (PHEIC) on May 17, 2026. Because no approved vaccines or specific clinical treatments currently exist for this strain, control efforts rely strictly on traditional public health measures: contact tracing, safe burials, and community engagement.
Are there any active treatment trials?
Clinical efforts are moving forward alongside diagnostic improvements. On July 2, 2026, researchers in the DRC enrolled the first patient in a major treatment trial. This study will involve over 1,000 participants and aims to evaluate the efficacy of two distinct medical interventions:
- MBP134: An experimental antibody treatment developed by Mapp Biopharmaceutical.
- Remdesivir: An antiviral drug produced by Gilead Sciences, tested both as a standalone treatment and in combination with MBP134.
According to the WHO, this trial is expected to span several months. Simultaneously, a joint validation platform involving partners like PATH, FIND, and CHAI is working to evaluate the performance of additional diagnostic products, including near-point-of-care molecular tests and antigen rapid diagnostic tests.
Frequently Asked Questions
What does the WHO Emergency Use Listing (EUL) signify?
The EUL is a risk-based procedure that assesses the quality and safety of unlicensed health products. Its purpose is to expedite the availability of diagnostics and treatments during public health emergencies.
Why is laboratory confirmation necessary for BVD?
According to the WHO, Bundibugyo virus symptoms closely resemble malaria and other febrile diseases. Laboratory tests are the only reliable way to differentiate the virus and ensure patients receive appropriate care.
Are there vaccines available for this outbreak?
No, there are currently no approved vaccines or specific treatments for the Bundibugyo virus, though clinical trials for antibody treatments are underway.
Stay informed on the latest developments in global health by subscribing to our weekly newsletter or exploring our interactive outbreak tracking map. Have questions about the diagnostic rollout? Leave a comment below.
